Condition: Myasthenia Gravis, Generalized · Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
The primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile.
This description comes directly from the study's public registry record.
Raffaele Iorio · +393347185128 · raffaele.iorio@policlinicogemelli.it
Always discuss trial participation with your own doctor first.
| Policlinico A. Gemelli IRCCS | Roma, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05868837